Therapeutic vaccines for high-risk HPV-associated diseases

Aleyo Chabeda, Romana J.R. Yanez, Renate Lampaecht, Ann E. Meyers, Edward P. Rybicki, Inga I. Hitzeroth

Department of Molecular and Cell Biology, University of Cape Town, Rondebosch 7701, South Africa
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa

ARTICLE INFO
Keywords:
Therapeutic vaccine
HPV
E6 and E7
Cervical cancer
Plant-based production

ABSTRACT
Cancer is the second leading cause of death worldwide, and it is estimated that Human papillomavirus (HPV) related cancers account for 5% of all human cancers. Current HPV vaccines are extremely effective at preventing infection and neoplastic disease; however, they are prophylactic and do not clear established infections. Therapeutic vaccines which trigger cell-mediated immune responses for the treatment of established infections and malignancies are therefore required. The E6 and E7 early genes are ideal targets for vaccine therapy due to their role in disruption of the cell cycle and their constitutive expression in premalignant and malignant tissues. Several strategies have been investigated for the development of therapeutic vaccines, including live-vector, nucleic acid, peptide, protein-based and cell-based vaccines as well as combinatorial approaches, with several vaccine candidates progressing to clinical trials. With the current understanding of the HPV life cycle, molecular mechanisms of infection, carcinogenesis, tumour biology, the tumour microenvironment and immune response mechanisms, an approved HPV therapeutic vaccine seems to be a goal not far from being achieved. In this article, the status of therapeutic HPV vaccines in clinical trials are reviewed, and the potential for plant-based vaccine production platforms described.

1. Introduction
Cancer is a global leading cause of death [1], and it is estimated that Human papillomavirus (HPV) related cancers account for 5% of all human cancers [2,3]. Cervical cancer is an important disease, more so than other cancers (breast, colorectal) as it affects women below the age of 45, resulting in more life years lost [4,5]. HPV is the most common cause of cervical cancer, the 4th most common cancer in women, which results in an estimated 528,000 cases and 266,000 deaths every year [6]. There are at least 170 HPV genotypes described, which are categorised into two groups: these are the low-risk types, including HPV-6/11/40/42/43/44/54/61 and -72 which cause genital warts, and high-risk (hr) types including HPV-16/18/31/35/39/45/51/52/56/58/66 and -68, which are responsible for 99.7% of cervical cancer cases [7-9]. HPV-16 and -18 are the most prevalent types associated with cervical cancer worldwide, causing more than 70% of cases. HPVs are also responsible for many penile, vulvar and anal carcinomas and contribute to over 40% of oropharyngeal cancers [10,11]. Persistent infection with hrHPVs results in the development of squamous intraepithelial lesions (SILs): in the cervix, these are also called cervical intraepithelial neoplasia, CIN; and in the vulva, vulval intraepithelial neoplasia (VIN). SILs can progress to malignant cancers [9].

1.1. HPV structure and pathogenesis
HPVs are small non-enveloped double-stranded DNA viruses with a genome size of approximately 8 kb [12]. The genome encodes for six early regulatory proteins - E1, E2, E4, E5, E6 and E7 - and the two late structural proteins L1 and L2. The early genes encode proteins responsible for viral DNA replication, transcription and oncogenic transformation, and the late genes encode the virus capsid proteins [13,14]. The capsid is 50–60 nm in diameter and is arranged in a T = 7 quasi-icosahedral formation consisting of 360 copies of L1 that assemble into 72 pentamers, with up to 72 copies of L2 integrated into each capsid [15,16].

HPV infects basal epithelial cells through anatomically accessible points such as microlesions in the skin, genital organs and oropharyngeal areas. Capsid proteins L1 and L2 attach to epithelial cell receptors and a long process of entry commences, resulting in cytoplasmic uncoating of the virus and entry of its genome into the nucleus of the
infected cell, where it is transcribed and then replicated. Early proteins are expressed first and regulate the host cell life cycle and genome replication. They also regulate the expression of late proteins in a cell differentiation-dependent manner: L1 and L2 are only expressed in mature squamous cells. Maturation of virions occurs after terminal differentiation of epithelial cells, and their release coincides with natural shedding of senescent cells at the end of the epithelial cell life cycle [9]. Most infections are cleared by the immune system [17,18]; however, some benign cervical lesions progress to cancer. Continuous infection results in low-grade CIN 1 lesions. Progression to high-grade CIN 2/3 lesions caused by hrHPVs leads to invasive cervical cancer (ICC), where the viral genome may integrate into the host genome [9]. Most infections are cleared by the immune system [17,18]; however, some benign cervical lesions progress to cancer. Continuous infection results in low-grade CIN 1 lesions. Progression to high-grade CIN 2/3 lesions caused by hrHPVs leads to invasive cervical cancer (ICC), where the viral genome may integrate into the host genome [9].

Fig. 1. The life-cycle of a typical hr-HPV. Infection occurs at basal epithelial cells through anatomically accessible points such as microlesions. The genomes of HPVs stay as episomes in the host's cell nuclei. Cells proliferate and differentiate. The expression of structural proteins, L1 and L2, viral assembly and release only occur at late stages of the cell life cycle. Integration of the viral genome into the host's genome leads to overexpression of E6 and E7 which disrupt the cell life cycle regulation which promotes prolonged cell life leading to genomic instability and cancer. At this stage no viral structural proteins are expressed. Adapted from Moody and Laimins [10].

1.2. Prophylactic vaccines and limitations

Currently, there are three commercially available HPV vaccines: these are Cervarix®, a bivalent HPV-16/18 vaccine; Gardasil®, a quadrivalent HPV-6/11/16/18 vaccine; and Gardasil®9, a nonavalent HPV-6/11/16/18/31/33/45/52/58 vaccine. All exploit the fact that HPV L1 protein can form virus-like particles (VLPs) when expressed alone in a variety of cell types, that are morphologically and antigenically highly similar to native virions [19]. These three vaccines effectively prevent HPV infections caused by the targeted types by eliciting the production of neutralising antibodies that bind to the viral particles and block their entrance into host cells [20-22]. However, these vaccines are not effective at eliminating pre-existing infections, since the target antigens, L1 capsid proteins, are not expressed in infected basal epithelial cells [23-25]. Therefore, the large number of individuals already infected with HPV do not benefit from the current vaccines. Developing countries carry the greatest burden of HPV infections and malignancies due to their lack of resources to implement efficient vaccination and screening programmes [8]. Thus, many women only detect infections when they have already progressed past CIN 1 or when cancer has already developed. Additionally, the high cost of these vaccines puts them out of the reach of low-income populations. Although HPV immunization programmes have been implemented in 76 countries and territories worldwide, only 1% of women in low and low-middle income countries are covered by these programmes [26]. Furthermore, the incidence of human immunodeficiency virus (HIV) has been shown to influence HPV acquisition, the prevalence of multiple HPV types, persistence of infection and alters the carcinogenicity of hrHPV types [27-32]. A meta-analysis looking at the carcinogenicity of HPV in HIV positive women worldwide, showed HPV-16, -18 and particularly HPV-45 in African women accounted for a greater proportion of HPV infection in ICC compared to normal cytology, and other high-risk types accounted for important proportions of other low and high-grade lesions [33]. Therefore, therapeutic vaccines that broadly target oncogenic HPV types, and that are inexpensive, are urgently required.

1.3. Therapeutic vaccines

Cell-mediated rather than humoral immune responses are important for the clearance of established infections. It has been observed that spontaneous clearance and slow progression of HPV infections are associated with a strong cell-mediated immune response involving mainly T-helper type 1 cells and cytotoxic T-cells derived from CD4+ and CD8+ T-cells, respectively [34]. The HPV E6 and E7 oncoproteins are essential for the onset and maintenance of malignancy; thus, they are unlikely to escape immune responses by mutation. They are also expressed constitutively and at high levels, and therefore represent near-
ideal targets for the development of therapeutic vaccines against established HPV infections and lesions [9,35,36]. Other proteins useful for targeting of early viral infections are E1 (viral helicase) and E2 which are expressed at higher levels than E6 and E7 at very early stages before viral genome integration [37,38]. An ideal therapeutic vaccine would target these proteins to induce strong tumour-specific T-cell type 1 and cytotoxic lymphocyte (CTL) responses able to kill infected and malignant cells [34]. However, there are currently no HPV therapeutic vaccines approved for use in humans. Nevertheless, there have been numerous and extensive studies that have generated promising vaccine candidates tested in clinical trials [39–41]. Despite the current success of these vaccine candidates, there remains the concern that conventional expression methods might result in expensive products [42,43] making them inaccessible to the poorer countries who have the highest incidences.

1.4. Reducing vaccine production cost

Plants represent an attractive alternative production platform due to their scalability, rapid production and low risk of contamination [44–46], compared to traditional microbial fermentation or mammalian and insect cell expression systems. Additionally, they contain the necessary eukaryotic machinery for protein modification such as protein folding and glycosylation [44]. It has been estimated that there could be a greater than 50% reduction in cost of goods, particularly associated with upstream processes, by using plants for production of vaccines [47].

Plants can be adapted to express heterologous proteins via transgenic or transient expression systems. Transgenic expression requires the integration of a transgene into the nuclear or plastid genomes of plants. This is achieved via transformation with the soil pathogen Agrobacterium tumefaciens, or by use of biolistics or microparticle bombardment [48,49]. Transient expression of recombinant proteins is facilitated mainly through Agrobacterium-mediated somatic gene transfer, where a T-DNA derived from the tumour-inducing (Ti) plasmid harbouring the gene of interest is transferred into the plant host genome with the help of virulence genes [50]. This system is advantageous as it allows for rapid protein production several days after cloning compared to the months needed for transgenic expression, expression levels are not affected by transgene insertions, and higher protein expression levels can generally be achieved compared to those achieved in transgenic plants [44,51]. The use of plant virus-based vectors is another method used for transient expression: this involves the use of infectious modified plant viruses (e.g. geminiviruses, tobamoviruses and bromoviruses [52–55]) to deliver a transgene to plant host cells, without the need for stable integration [56]. These vectors can potentially allow systemic spread of the virus, which is advantageous as it means very little inoculum is required. Several plant-made vaccines against cancer have been developed using viral vectors and peptide/protein-based strategies, and it is thought that these have potential for reaching the market [57].

In this article we review the various therapeutic vaccine strategies that have been explored, including live vector, nucleic acid, protein, whole cell and combinatorial vaccines. Their advantages and disadvantages are highlighted, some important examples of each strategy are discussed, and ongoing clinical trials are summarised. In addition, the current status of plant-made therapeutic vaccine candidates will be highlighted.

2. Therapeutic vaccine strategies

2.1. Live vector vaccines

Live vector vaccines are recombinant bacterial or viral vectors that can replicate inside the host cells, facilitating the spread of antigens. They can drive antigen presentation through both major histocompatibility complex (MHC) class I and class II pathways, stimulating CD8+ cytotoxic T-cells and CD4+ helper T-cells respectively, thus providing high levels of immunogenicity [35].

2.1.1. Bacterial vectors

Bacterial vector species include Listeria monocytogenes, Lactobacillus casei, Lactobacillus lactis and Salmonella. Listeria is a promising vector due to properties such as its ability to infect macrophages without being captured by phagocytosis, and its ability to direct antigen processing via MHC I and MHC II pathways [58,59]. It also evades phagosomal lysis through secretion of listeriolysin O (LLO) [60]. L. monocytogenes (Lm) is of particular interest for vaccine development since it is able to act as a natural adjuvant. A phase I clinical trial of an E7-based vaccine called Lm-LLO-E7 in 15 patients with metastatic or advanced cervical cancer, showed an increase in E7-specific IFNγ+ T cells in 3 patients and reduction in tumour size in 4 patients [61]. Based on this study, Advaxis Inc. have designed and planned additional phase I and/or II clinical trials with ADXS11-001, in patients with metastatic anal cancer, squamous cell carcinoma (SCC) of the rectum, metastatic cervical cancer, head and neck cancer, or SCC or non-SCC of the cervix (NCT01671488, NCT02164461, NCT02291055, NCT01266460, NCT02399813 and NCT02002182) [40,62]. A phase III trial for high-risk and advanced cervical cancer (AIM2CERV) is currently recruiting participants (NCT02853604). Oral administration of a L. casei bacterial vector vaccine GLBL101c, expressing a modified HPV-16 E7, was recently tested in a phase I/IIa clinical trial in 17 patients with HPV16+ CIN3. There was a significant increase in E7 cell mediated immunity, with 9 patients showing regression to CIN2, and 5 progressing to LSIL. No adverse side effects were experienced by any patients and this study was the first report of a therapeutic HPV vaccine to induce anti-neoplastic immunity [63].

2.1.2. Viral vectors

The efficacy of viral vectors such as adenoviruses, alphaviruses, fowlpox and vaccinia viruses has been investigated in preclinical models [25,62,64]. Vaccinia virus vectors have shown the most promise for antigen-specific immunotherapy [25,39]. In clinical trials, recombinant modified vaccinia virus Ankara (MVA) viral vectors expressing HPV-16 or -18 E6 or E7 (TA-HPV) showed HPV-specific CTL responses in 28% of patients with advanced cervical cancer in a phase I/II study [65,66], and at least a 40% reduction in lesions in 83% of patients aged 42–54 with high-grade vulval or vaginal intraepithelial neoplasia in a phase II study [67]. Most recently, a vaccine based on HPV-16 E2 (MVA E2) was shown to have 90% efficacy in the treatment of HPV-induced anogenital intraepithelial lesions in a phase III study in 1356 male and female patients [68]. Additionally, all males showed complete eradication of lesions, and HPV-specific CTL T cell responses were observed. E2 is a protein inhibitor for the expression of E6 and E7 [69,70], and has been shown to arrest cell growth and induced apoptosis of cancer cells [71]. Therefore, vaccination with E2 may suppress E6 and E7 activity in the infected host, thereby reducing the transformation ability of infected cells and survival of HPV tumour cells. Another MVA vector - TG4001, based on HPV-16 E6/E7 and IL-2 - showed 10 out of 21 patients as clinical responders after 6 months, regression of CIN 2/3 in 7 out of 10 patients and 7 out of 8 patients showed no relapse of CIN 2/3 or HPV-16 infection after 12 months [72].

RNA replicon vaccines can be derived from RNA alphaviruses such as Sindbis virus (SIN), Venezuelan equine encephalitis virus (VEE) and Semliki forest virus (SFV) [73]. RNA replicons are capable of self-replication, resulting in sustained antigen expression and thus an increase in immunogenicity [35]. Mice vaccinated with recombinant SIN replicon VP22-E7 particles expressing the herpes simplex virus type 1 tegument protein linked to HPV-16 E7 showed a significant increase in E7-specific CD8+ T cells, and there was a strong antitumour effect [74]. A VEE E7 replicon particle (E7-VRP) vaccine prevented tumour development in all mice and showed complete protection from tumour
challenge after 3 months. In a different therapeutic experiment, E7-VRP also eliminated 7-day established tumours in 67% of tumour-bearing mice [75]. In another study, a VEE E6/E7 vaccine protected 100% of mice from C3 or TC-1 tumour challenge, and eradicated C3 tumours in 90% of mice [76]. Immunization of mice with SFV replicons encoding E6 and E7 resulted in strong HPV-specific CTL responses, and the regression and elimination of established tumours [77–80]. Vvax001, a replication incompetent SFV HPV-16 E6/E7 vector, is being tested in humans for the first time. A phase I trial to investigate the immune modulating effects and safety of Vvax001 is currently recruiting participants (NCT03141463).

However, there remain challenges in the use of live vector vaccines due to potential dominance of the immune response to the viral vector instead of the HPV antigen, pre-existing immunity, the generation of neutralising antibodies which restrict repeated therapy, and the potential pathogenicity of the vector particularly in immunocompromised individuals [35,81,82].

2.2. Subunit vaccines

Subunit vaccines are antigens delivered in the form of peptides or whole proteins. They are regarded as safer than live vector vaccines for they are present in the host cells transiently, decreasing the chances of toxicity.

2.2.1. Peptide vaccines

Peptide vaccines are stable, safe and easy to produce; however, they are often MHC specific and need to match the patient's human leukocyte antigen (HLA) type for effective presentation. Therefore, immunogenic epitopes need to be identified for each individual which makes this strategy impractical to implement in mass vaccinations [83,84]. In addition, they have poor immunogenicity and require administration with molecules or adjuvants such as cytokines and Toll-like receptor (TLR) ligands, to improve vaccine potency for strong CD8+ T cell responses [35,40,85]. To overcome the HLA limitation, synthetic long overlapping peptides (SLPs) that contain E6/E7 peptides have been used and been shown to improve T cell responses. In a phase II clinical trial, vaccination of women positive for HPV-16 CIN 3 with a mixture of HPV-16 E6 and E7 SLPs and adjuvant induced the activation of CD4+ T-cells and CTL responses. At the end of the trial, 79% of women vaccinated showed positive clinical responses and 45% had complete regression of the lesions 12 months after vaccination [86]. In another phase II clinical trial, patients that had advanced or recurrent HPV-16-associated cervical cancer were treated with a mixture of 13 overlapping SLPs covering the entire sequences of HPV-16 E6 and E7. Of 16 patients tested, 56% showed vaccine-induced HPV-specific T-cell proliferation, and 85% of the 13 patients tested showed vaccine-induced immune responses. Furthermore, those with a longer survival time showed a stronger response than those that lived relatively shorter after vaccination, as seen by increased lymphocyte stimulation and anti-tumour agents such as INF-γ and α, and IL production [87]. A phase II trial with ISA101 (9 HPV-16 E6 and 4 E7 SLPs) and the drug Nivolumab is ongoing in the treatment of patients with solid tumours (NCT02426892). A phase I clinical study using PepCan, a vaccine that consists of 4 HPV-16 E6 synthetic peptides and a novel adjuvant Candidin, in patients with HSIL showed that 45% of patients had regression of disease, and significant decreases in viral load [88]. A 2-arm therapy phase II trial to evaluate the efficacy and safety of PepCan (arm 1 - PepCan; arm 2 - Candidin) is currently recruiting participants (NCT02481414). Another phase I study to determine the biological activity of Hesperata (HPV-16 E6 71–95 and E6 127–158 SLPs coupled to Amplivant, a synthetic TLR 2 ligand), in the treatment of HPV + tumours or premalignant lesions is recruiting patients (NCT02821494). A phase Ib/II trial in HLA-A*02 + patients with incurable HPV + head and neck, cervical, or anal cancer is currently recruiting participants (NCT02865135). This study aims to test the safety and efficacy of DPX-E7, a synthetic peptide consisting of HPV16-E7 amino acids 11–19, in combination with cyclophosphamide. The future of peptide-based vaccines is dependent on their immunogenicity and antigen presentation.

2.2.2. Protein-based vaccines

Unlike peptide-based vaccines, protein-based vaccines contain all antigenic HLA epitopes therefore are not MHC restricted; however, they show low immunogenicity and promote antibody responses over T cell responses due to presentation to the MHC II complex [84]. Efforts to increase immunogenicity and presentation to the MHC I pathway and activation of CD8+ T cells include the creation of fusion proteins to target antigen to dendritic cells (DCs) and the use of adjuvants [35,89]. TA-CIN is a subunit vaccine (fusion protein composed of HPV-16 L2, E6, and E7) and has been proven safe in a number of clinical trials [90–92]. In a phase II trial treating VIN2/3, it was shown that after vaccination with TA-CIN there was an increase in CD4+ and CD8+ T cells and complete regression of VIN in 63% of patients 1 year after vaccination [93]. A phase I study to evaluate the safety of TA-CIN as an adjuvant therapy in patients with HPV-16 associated cervical cancer is expected to commence in November 2017 (NCT02405221). Fusion proteins targeting proteins to the endoplasmic reticulum (ER) have also shown improved CTL responses. A HPV-16 E7 fusion peptide, TVGV-1 (TheVax Genetics Vaccine Co.), with GP100 adjuvant, demonstrated strong HPV-specific E7 CTL responses and protection from tumour challenge and a phase Ia clinical trial is currently underway in patients with HSIL (NCT02576561). Several other clinical trials are ongoing testing the potential of therapeutic protein vaccines [39,40]. Overall, the enhancement of immunogenicity and CD8+ T cell responses is key to the future of protein-based vaccines.

Granadillo et al. [94] developed a novel fusion protein vaccine consisting of the HPV-16 E7 protein and a peptide derived from the Limulus polyphemus anti-lipopolysaccharide factor (LALF31–52) in an E. coli expression system. LALF31-52 is a small and hydrophobic peptide that can penetrate cell membranes, and which has immunomodulatory properties [95]. Fusion of LALF31–52 to E7 (LALF-E7) increased the immunogenicity and aided in antigen presentation of E7. In a prophylactic experiment, vaccinated mice were protected against E7-expressing TC-1 cell tumour challenges. In a therapeutic experiment, tumour-bearing mice showed tumour-specific immune responses and tumour regression. The tumour protection and tumour regression were significantly higher when compared to control mice vaccinated with E7 or LALF alone. Furthermore, the anti-tumour effect of LALF-E7 was comparable in the presence or absence of an adjuvant [94]. These results confirmed the potentiating effect of the cell-penetrating peptide, and showed that LALF-E7 is promising as a HPV therapeutic vaccine.

2.2.3. Plant peptide/protein-based vaccines

The use of plant-based viral vector vaccines for protein production could both increase vaccine yield and shorten production time [55]. Plant-made early protein-derived vaccines tested in mice have elicited humoral and cell-mediated immune responses, and protection against tumour challenge. HPV-16 E7 expressed using a potato virus X (PVX) replicating vector in Nicotiana benthamiana showed E7-specific CTL responses in mice. The animals showed both Th-1 and Th-2 responses, and after challenge with C3 cells, tumour growth was inhibited in 40% of mice [96]. Tumour growth was further inhibited in 80% of mice in another study by the same group, where E7 expression was enhanced 5-fold by targeting to the plant secretory pathway [97]. The authors also suggested that plant extracts may have adjuvanting properties as mice showed a stronger immune response when vaccinated with the leaf extracts without adjuvant, and at a 20-fold lower dose than is known to prevent tumour growth, compared to the positive control group vaccinated with Escherichia coli produced E7 and Quil A adjuvant [97]. In another study, the HPV-16 E7 mutant E7GGG (E7 without a Rb binding site) fused to Clostridium thermocellum β-1,3-1,4-glucanase or LicKM
was expressed via recombinant tobacco mosaic virus (TMV). Vaccinated mice had strong humoral and cell mediated responses and tumour growth was inhibited in all animals [98,99].

DNA encoding E7GGG was introduced into the chloroplast genome of the unicellular alga Chlamydomonas reinhardtii by homologous recombination. Sixty percent of mice injected with purified protein were protected from tumour growth, and growth was slowed in mice that developed tumours compared to the control group [100], showing that this vaccine candidate expressed in an algal system retained its therapeutic relevance. Additionally, the E7 protein in this study was soluble compared to most other E7 proteins that are insoluble, giving it the advantage of more cost-effective downstream processing. C. reinhardtii is easy to grow and transform and fully amenable to Good Manufacturing Practice (GMP) guidelines, making this a potential ideal system for vaccine production [100].

More recently, HPV-16 E7 protein bodies made in N. benthamiana by Agrobacterium-mediated transient expression were shown to elicit tumour regression in mice [101]. A shuffled E7 sequence that has no transformation ability, but which contains natural CTL epitopes [102], was fused to Zera* (Zip* Solutions, Spain), a peptide that has been shown to result in the high-level accumulation of recombinant proteins in the ER. These are localised in large, stable protein bodies that are protected from degradation and are easy to purify [103,104]. Humoral and potent cellular immune responses were stimulated in a murine model and results were comparable to a gold standard DNA vaccine previously tested. The use of Incomplete Freund's adjuvant (IFA) in the immunization and potent cellular immune responses were stimulated in a murine model and results were comparable to a gold standard DNA vaccine previously tested. The use of Incomplete Freund’s adjuvant (IFA) in the murine system for vaccine production [100].

Yanez et al. [105] have successfully expressed the LALF-E7 vaccine described above in N. benthamiana. The highest expression levels were obtained with a self-replicating plant expression vector and chloroplast targeting, which increased accumulation 27-fold over cytoplasmic localisation. LALF<sub>2p-51</sub>-E7 was indeed targeted to the chloroplasts by the chloroplast transit peptide used, and moreover formed aggregated PB-like structures [106]. Production and extraction of the antigen was scaled up and purification was optimised by affinity chromatography; however, further optimisation of purification protocols is required before determining its therapeutic potential in animal studies.

2.3. Nucleic acid vaccines

2.3.1. DNA vaccines

DNA vaccines are safe, easy to manufacture and purify, promote MHC I antigen presentation, and unlike live vector and protein vaccines, do not produce neutralising antibodies to the vector, allowing for repeated vaccination [107]. DNA vaccines have been extensively studied and proven to be safe in clinical studies [39,40]. The potential risk of DNA plasmids integrating into the host genome for HPV vaccines in particular has been addressed with the use of modified E6 and E7 genes that do not encode proteins with oncogenic transformation properties. However, DNA vaccines alone have been found to be poorly immunogenic. To increase their potency, strategies such as increasing the number of antigen expressing/antigen-loaded DCs, improving antigen presentation and processing, and enhancing DC and T cell interaction have been developed [108,109]. To enhance antigen processing and presentation by DCs, Kim et al. [110] designed the DNA vaccine GX-188E (Genexine, Inc.) that co-expressed the HPV-16 and -18 antigens E6 and E7, and the Fms-like tyrosine kinase-3 ligand (Flt3L). The latter is a known DC activator and is commonly used in anti-cancer vaccine designs [111-113]. A phase I study in 9 patients with HPV-16/18+ CIN 3 elicited HPV-16 and -18 E6 and E7 specific cell-mediated responses including IFN-γ-secreting CD8+ and CD4+ T-cells, and showed HPV-specific polyfunctional CD8+ T cell responses, with 7 patients showing complete lesion regression at the end of the study [110]. A phase II trial in women with HPV-16/18+ CIN 3 lesions (NCT02139267) has been completed and another phase II trial in women with HPV-16/18+ CIN 2, CIN2/3 or CIN 3 (NCT02596243) is ongoing, with expected completion in 2018. A phase Ib/II trial to investigate the safety and efficacy of GX-188E administered intramuscularly with local administration of immunomodulators GX-I7 or Imiquimod in women with CIN 3, is currently recruiting participants (NCT03206138).

Vaccine delivery by electroporation, encapsulation, gene gun or laser therapy have also been described as methods to enhance immunogenicity [41] as they can increase the number of antigen-expressing/antigen-loaded DCs [114]. VGX-3100 (Inovio Pharmaceuticals, Inc.) is a DNA vaccine based on HPV-16/18 E6/E7, and is delivered via intramuscular injection followed by electroporation in the form of a small electrical charge. A phase I clinical trial in 18 patients who had been previously treated for CIN 2/3 showed that 14 patients (78%) developed HPV-specific CD8+ T cell responses, 17 patients (94%) had increased HPV-16 E7 antibody titres and all patients had increased HPV-18 E7 antibody titres. Furthermore, 12 patients (67%) and 7 patients (39%) had increased HPV-16 E6 or HPV-18 E6 antibody titres, respectively [115]. A follow-up phase Ib trial was conducted based on the robust antigen-specific immune responses observed and the potential to contribute to the eradication of HPV-infected cells and lesion regression. In a randomized, double blind, placebo controlled study, patients with CIN 2/3 lesions showed greater HPV-specific humoral and T cell immune responses and lesion regression accomplished by viral clearance [116]. VGX-3100 is the most successful DNA vaccine to date; it is being tested in a phase I/IIa trial in patients with HPV-associated head and neck cancer (NCT02163057) [117], as well as in a phase I/IIa trial in women with new, recurrent or persistent cervical cancer (NCT02172911). A phase II randomized, double blind, placebo controlled study (REVEAL 1) in women with confirmed CIN 2 or 3 is currently recruiting participants (NCT03185013). Another DNA vaccine, VB10.16, is in phase I/IIa to test its safety and immunogenicity in patients with CIN 2/3 (NCT02529930).

Most recently, genome editing tools such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats/Cas9 protein (CRISPR/Cas9) in the treatment of HPV-induced cancers have been shown to induce apoptosis, inhibit growth and reduce tumorigenicity in HPV+ cell lines, and to reduce the viral load in transgenic mouse models [118-124]. A phase I study to determine the efficacy of ZFN-603 and ZFN-758, which can cleave HPV-16/18 E7, in the treatment of cervical precancerous lesions has recently been completed (NCT02800369). A phase I study to test the efficacy and safety of TALEN-HPV-16 or -18 E6/E7 plasmid or CRISPR/cas9-HPV-16 or -18 E6/E7 plasmid in the treatment of HPV-related CIN is expected to begin in January 2018 (NCT03057912).

2.3.2. RNA replicon-based DNA vaccines

Single-stranded RNA vaccines have similar properties to DNA vaccines in that they are safe, do not generate neutralising antibodies and therefore can be administered multiple times. Additionally, replicating versions based on RNA viruses can replicate in various cell types [125] and pose no risk of chromosomal integration or cellular transformation. However, they are difficult to make and also cannot spread intercellularly. Suicidal DNA vaccines, where an RNA replicon is encoded in a DNA vaccine, have been designed to overcome this problem. Suicidal DNA is translated into RNA in transfected cells and triggers apoptosis, ensuring genomic integration cannot occur. However, due to apoptosis of transfected DCs, this strategy has led to poor immunogenicity [40]. To overcome this issue, the inclusion of an anti-apoptotic gene in suicidal DNA to enhance survival of APCs has been described in a preclinical model [126]. The use of a flavivirus Kunjin (KUN) vector [125,127], also allows and prolongs direct antigen presentation by transfected DCs. The latter approach elicited E7-specific T cell responses and was protective in mice challenged with an E7-expressing...
tumour [127]. RNA vaccines for other cancers have progressed to clinical trials [73,128]; however, there remains a lot of work to be done in the development of HPV RNA vaccines.

2.4. Cell-based vaccines

Cell-based vaccines involve the isolation of target cells such as DCs or T cells from the patient, manipulation ex vivo, and transfer back to the patient for treatment.

2.4.1. Dendritic cell-based vaccines

The use of DCs is attractive because these cells are the major antigen presenting cells that can activate CD4+ and CD8+ T-cells [89], bypassing the need to enhance antigen visibility that is faced by protein or DNA vaccines. DCs are advantageous as they can act as natural adjuvants and increase the potency of the specific antigen [129]. DCs can either be loaded with HPV-specific peptide/protein antigens or transduced so as to express antigens, which are then delivered back to the patient [130]. A phase I study with full-length HPV-16 and -18 E7 and keyhole limpet hemocyanin (KLH) showed an increase in E7-specific CD4+ T cells in patients with stage Ib or IIa cervical cancer, and 8 out of 10 patients showed production of E7-specific CD8+ T cells [131]. Additionally, the vaccine was well tolerated in all patients. In a similar study of DCs loaded with HPV-16 or -18 E7 co-administered with IL-2, specific CD4+ T cell responses were detected in 2 out of 4 patients and E7-specific CD8+ responses observed in all patients [132]. Pre-immune DCs (PIDCs) (cells lacking full T cell co-stimulatory activity, [89]) have also been shown to be effective in the treatment of patients with advanced cervical cancer. PIDCs pulsed with HPV-16 E6 or E7 induced specific immune responses in 63% (E6) or 58% (E7) of patients [133]. Other antigen presenting cells have been used to evaluate the immune response in patients with advanced or recurrent cervical cancer. Participants are currently being recruited for a phase I trial for BVAC-C, a recombinant HPV16/18 E6/E7 expressing adenosivirus-infected B cells and monocytes (NCT02866006).

DC-based vaccines have several limitations, however, as they are restricted in their capacity for large-scale production due to the requirement of harvesting sufficient DCs from each patient, do not have a defined route for vaccination (critical for priming of T cells), show inconsistent vaccine quality due to variations in cell culture technique, and they have a limited lifespan due to T-cell mediated apoptosis [40,41,62]. To address their short life span, short interfering RNA (siRNAs) targeting pro-apoptotic molecules have been explored, which have shown enhanced E7-specific CD8+ activation and anti-tumour effects in mice [134–136]. Additionally, handling of human cells ex vivo requires high technical competence, is labour-intensive, time consuming and costly, making this strategy impractical to implement for large scale vaccinations [35,36]. The use of PIDCs over mature DCs has the potential to reduce vaccine production cost [133]; however, further clinical study into whether DC maturation is necessary to generate an immune response is required.

2.4.2. Adoptive cell transfer

Adoptive cell transfer (ACT) involves the generation of antigen-specific CTLs ex vivo, which are then used in vivo to enhance immunogenicity. This technique is advantageous as it generates antigen-specific CTLs that can be produced in large quantities in vitro; CTLs can be engineered or activated ex vivo to obtain antigenic functions; and it allows for manipulation of the host before cell transfer to eliminate suppressor cells such as regulatory T cells, or Tregs [62]. A pilot study in 9 patients with metastatic cervical cancer showed complete regression in 2 patients after treatment with HPV-16 E6 and E7 reactive CTLs [137]. In another study, T cell receptors against E6 were introduced into CTLs, which killed HPV+ cells from cervical and head and neck cancer cell lines [138]. Most recently, a phase I/II clinical trial (NCT02280811) targeting several HPV-associated cancers (cervical, anal, vaginal and oropharyngeal) showed regression of metastatic HPV + carcinoma in 2 of 12 patients, suggesting that T cell receptor therapy can facilitate epithelial cancer regression [139]. A phase I trial using T cells genetically engineered with T cell receptors targeting HPV-16 E7 with or without programmed cell death protein 1 (PD-1) blocking drugs (PD-1 is an inhibitory receptor on T cells), in patients with cervical, vaginal, anal, penile or oropharyngeal cancers, is currently recruiting participants (NCT02858310). A phase I trial using HPV-16 E6 T cell receptors for the treatment of high-grade VIN is also recruiting participants (NCT03197025).

A new experimental treatment is using HPV-specific T-cells (HPVST) derived from the blood of patients with HPV cancers, and determining if these cells can survive in the blood and affect the HPV-associated tumour [140]. Additionally, to make the T cells more active, they have been engineered to make them resistant to transforming growth factor beta (TGF-β) which is produced by HPV cancers [141]. A phase I trial in patients with relapsed HPV-associated cancers (HESTIA) is currently recruiting participants to investigate the safest dose, side effects and how long HPV-16/18 E6/E7 HPVSTs last in the body (NCT02379520).

Most recently, chimaeric antigen receptor (CAR) T cell therapy is being investigated in the treatment of cervical cancer. CAR T cells are designed to express receptors that redirect polyclonal T cells to surface-exposed tumour-associated antigens (TAAs) for subsequent tumour elimination [142]. A phase I/II study is currently recruiting participants to assess the feasibility, safety and efficacy of CAR T cells in patients with TAAs GD2, PSMA, Muc1, Mesothelin or other markers positive for cervical cancer (NCT03356795).

However, it is thought that CTLs alone may not be enough to eliminate cancer cells in patients with advanced disease. HPV cancers evade the immune system and treatment of solid tumours remains a challenge. Effective T cell therapy will need to improve and address concerns such as tumour heterogeneity, antigen escape, an immunosuppressive microenvironment, inhibition of T cell localisation [139–141] and methods to improve the state of leaky and fragile blood vessels that supply tumour cells [143,144].

2.5. Combining different therapeutic strategies

The diversity of current therapeutic vaccine candidates for HPV-related malignancies offers an opportunity to combine some of the strategies and to better exploit their potential. Combination treatments could be the key to successful treatment of HPV lesions [145].

2.5.1. Prime-boost regimens

Heterologous prime-boost regimens can be used to enhance vaccine potency: for example, one may prime the immune system with a DNA-based vaccine, followed by a boost with a virus-based vaccine. Evaluation in clinical trials of prime-boost regimens has also been explored. In a phase II clinical trial, TA-CIN fusion protein vaccine was boosted with recombinant vaccinia virus TA-HPV in 29 patients with anogenital intraepithelial neoplasia, with 5 patients showing increased HPV-16 antigen-specific T cell-mediated immune responses [146,147]. However, this result was not significant over TA-HPV vaccination alone. In another study, 10 patients with HPV-16+ high grade VIN were this time primed with TA-HPV and boosted with TA-CIN. Nine patients showed HPV-16 specific T-cell responses and 3 patients had a significant reduction in lesions. However, these results did not show a direct correlation between clinical and immunological responses [90].

More recently, in a phase I trial (NCT00788164) in patients with CIN 3, a pNGVL4a-sig/E7(detox)/HSP70 DNA prime followed by TA-HPV boost in combination with imiquimod was being used to evaluate therapy. pNGVL4a-sig/E7(detox)/HSP70 DNA vaccine has previously been shown to elicit systemic HPV-specific CD8 T-cell responses in women with CIN 2/3 that could traffic to the lesion, and regression was observed in some patients [148].

A. Chabeda et al. Papillomavirus Research 5 (2018) 46–58
2.5.2. Immunomodulators

Vaccines with immunomodulatory agents that influence the tumour microenvironment can increase the success of therapeutic vaccines. There are several targets for immune modulation, including Tregs, tumour-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) [149]. Tregs release immunosuppressive cytokines (e.g., IL-10) and transforming growth factors which can affect T cell function. Depletion of CD4+ and CD25+ Tregs have been shown to enhance E7-HSP70 vaccine potency [150]. Therefore, controlling the effects of these factors could deprive tumour cells of important growth factors and enhance the anti-tumour response of therapeutic vaccine candidates [149,151,152]. IRX-2, a biological product containing multiple cytokines (e.g., IL-2, IL-β, IFN-γ and TNF-α) and produced by stimulation of mononuclear cells, has been shown to activate different cells of the immune system [153,154] and the ability to potentiate antitumour effects of immune cells, such as upregulation of key signalling molecules’ expression on DCs [155,156]. IRX-2 in combination with cyclophosphamide, indomethacin, zinc-containing multivitamins and omeprazole (IRX-2 Regimen) has been studied in patients with squamous cell carcinoma of the head and neck [157–160], and shown promise as a novel immunotherapeutic. A phase II trial in patients with CIN or VIN 3 is currently recruiting participants (NCT03267680).

In plants, the immunomodulatory properties of *N. benthamiana* leaf extracts has been demonstrated by Di Bonito et al. [161], who tested the effect of leaf extracts containing E7 on human monocyte derived DCs. The vaccine NbPVX-E7 (HPV-16 E7 protein expressed by a PVX-derived vector) was able to prime human blood-derived lymphocytes from healthy individuals and induce E7-specific cytotoxic activity, thereby showing the potential for their use in the immunotherapy of HPV-related lesions.

2.5.3. Checkpoint inhibitors

Immune checkpoint inhibitors disrupt cell signalling which prevents cancer cells from avoiding T-cell mediated death [162,163]. PD-1 and cytotoxic T lymphocyte-associated transmembrane receptor 4 (CTLA-4) are immune checkpoint receptors expressed on the surface of CTLs, and interact with PD-L1 (programmed death-ligand 1) and CD80/CD86, respectively, on APCs resulting in attenuation of CTL activation [164]. Checkpoint inhibitors are advantageous over ACT therapies as they can easily be used across a number of tumour types, and do not rely on cancer-specific antigens [62]. A phase I study testing Ipilimumab, an anti-CTLA-4 monoclonal antibody, together with chemoradiation therapy is being tested in patients with advanced cervical cancer (NCT01711515). Ipilimumab is also being tested in a phase II trial in patients with HPV+ metastatic or recurrent cervical cancer (NCT01693783). A phase Ib/II trial testing TG4001 in combination with the Avelumab (human anti-PD-L1 IgG1 monoclonal antibody), in patients with oropharyngeal squamous cell carcinoma of the head and neck or metastatic malignancies is recruiting participants (NCT03260023). Dual checkpoint inhibition is being tested in 2 phase I studies with MEDI4736 (anti-PD-L1 antibody) and tremelimumab (anti-CTLA-4 antibody), in patients with advanced solid tumours (NCT02261220) and cervical cancer (NCT01975831).

2.5.4. Non-specific immunostimulants

TLR agonists are immunopotentiators which have been shown to increase activation of cell-mediated responses and viral clearance [165]. Wick and Webb [166] designed a broad-spectrum HPV therapeutic vaccine, Pentarix, consisting of the E7 sequences from the major hrHPV types 16, 18, 31, 45 and 52 that account for more than 80% of cervical cancers. They previously showed that proteins can elicit a strong cell-mediated response extracellularly when accompanied by a TLR3 agonist, poly(I:C) [167]. Here they also tested the TLR9 agonist CpG DNA. Mice vaccinated with Pentarix and either one of the adjuvants showed regression of TC-1-induced tumours after one week of vaccination. They had a complete tumour regression by week three post treatment, and remained tumour-free for at least three months. Furthermore, they showed that claster immunization of mice with Pentarix + poly(I:C) increased the cell-mediated responses in mice as well as the rate of tumour regression compared to mice vaccinated only once. Their findings suggested that the vaccine was able to elicit a cell-mediated response strong enough to overcome the immunosuppressive tumour microenvironment. Pentarix could be used as a broad spectrum treatment for a variety of HPV-related pre- and cancerous conditions [166]. A patent for Pentarix was filed in 2012; however, no information on future clinical trials was available.

2.5.5. Therapeutic vaccines with other therapies

Therapeutic treatments such as chemotherapy and radiotherapy have been used in conjunction with candidate therapeutic vaccines. In a phase II clinical trial, women with VIN 2 and 3 were treated with the topical immunomodulator imiquimod, followed by 3 doses of TA-CIN. One year after the last immunization, 63% of patients showed lesion clearance, and had increased CD4+ and CD8+ T cells compared to non-responders. In addition, 36% of patients showed HPV-16 clearance and 79% were symptom-free [93]. In ongoing trials, ISA101/ISA101b in combination with chemotherapy drugs carboplatin and paclitaxel, and with or without bevacizumab, is currently being tested in patients with cervical cancer (NCT02128126) in a phase I/II study. Another phase Ib/Iia study is recruiting patients with recurrent/metastatic HPV-associated head and neck squamous cancer, to test the anti-tumour activity and immunogenicity of MEDI0457 (VXG-3100 DNA vaccine) in combination with durvalumab (anti-PD-L1 monoclonal antibody) (NCT03162224).

2.5.6. Combination prophylactic and therapeutic vaccines

Combination vaccines would be beneficial in providing immediate impact and long-term protection through mass immunization of pre-adolescents and older women who have previously been exposed to HPV infection [168]. Chimaeric proteins and pseudovirions (PsVs) delivering a DNA vaccine are current strategies to produce combination vaccines.

2.5.6.1. Chimaeric vaccines

Several groups have developed L1/E7 chimaeras where full length or N-terminal regions of E7 have been fused to the L1 C-terminus [169–176] or fused to the C-terminal of L2 to create L1/L2/E7 chimaeras [177–181]. A clinical study in 39 women with CIN 2/3 showed that vaccination with L1:E7 chimaeras induced high anti-L1 antibody titres and low anti-E7 antibody titres, in addition to cellular immune responses to both L1 and E7. Improvement to CIN or normal tissue was seen in 39% of patients compared to 25% in the placebo group, with 56% of patients being HPV-16 DNA negative at the end of the trial. However, clinical efficacy was not significant [173]. In plants, L1:E6:E7 chimaeras have been produced in transgenic tomato [182]. The chimaeras elicited neutralising antibodies and elicited cytotoxic T cell responses to L1 and E6/E7 in mice. In a follow up study looking at the persistence of specific IgG antibodies and the therapeutic potential of L1:E6:E7, IgG antibodies were shown to be persistent for over 1 year and there was a 57% reduction in tumour growth in immunized mice [183].

2.5.6.2. Pseudovirions (PsVs) in gene delivery. HPV PsVs have emerged as a viable means of DNA and RNA delivery into several cell types and tissues. PsVs have several advantages as they have been shown to act as adjuvants and can facilitate the activation and maturation of APCs such as DCs [180,184–186], and do not have safety concerns, unlike live vector vaccines [185]. Packaging of plasmid DNA allows for stimulation of both humoral and cellular immunity [187]. In vivo, PsVs have been used in gene therapy experiments for ovarian cancer. HPV-16 PsVs were used to deliver a herpes simplex thymidine kinase (HSV-tk) gene to ovarian tumour cells in mice and were shown to have antitumour effects [188]. Delivery of the model ovalbumin (OVA) antigen in HPV-
16 PsVs was also shown to generate OVA-specific CD8+ T cells immune responses in mice, the highest number of OVA-specific CD8+ T cells compared to DNA delivery by other methods [185,189], and potent neutralising responses when DNA was co-administered with capsid proteins [190]. An alternative approach using short hairpin RNA (shRNA) has also been reported. HPV-31 PsVs encoding shRNA against E6 or E7 were used to silence E6 or E7 expression in cervical carcinoma cells. shRNA was delivered to CaSki and TC-1 HPV+ cells and resulted in the degradation of E6 and E7 mRNAs, with more significant cell death observed when E7 expression was suppressed, and in vivo testing in mice resulting in the dramatic inhibition of tumour growth [191].

HPV PsVs have recently been produced in plants for the first time [192]. Secreted alkaline phosphatase and luciferase encoding reporter plasmids were designed based on the genome of the bean yellow dwarf geminivirus and successfully packaged in plant-made PsVs. These PsVs were shown to be capable of infecting mammalian cells, could deliver a functional reporter plasmid for use in pseudovirion-based neutralisation assays and could be neutralised by anti-L1 monoclonal antibodies. This shows the potential of these PsVs to package and deliver HPV nucleic acid therapeutics. Additionally, plant made PsVs could offer a cheaper alternative to current PsV production methods that require cultured mammalian cells and expensive media and transfection reagents.

A summary of the mechanism of action of an ideal HPV therapeutic vaccine is shown in Fig. 2. Furthermore, a summary of HPV therapeutic vaccines in ongoing clinical trials is given in Table 1.

3. Future perspectives for HPV therapeutics

With several candidate vaccines in clinical trials, it is likely that we will see a therapeutic HPV vaccine on the market soon. However, current therapeutic strategies remain expensive due to systems of manufacture, meaning even if a vaccine were to be commercialised, its cost would render it less accessible to populations in developing countries where the burden of cervical cancer is highest. To expand the impact of therapeutic vaccines in developing countries, plant-made products are a promising technology to offer inexpensive and efficacious pharmaceuticals [55]. Additionally, cold-chain vaccine delivery is necessary to maintain vaccine shelf life, and contributes to the inaccessibility of vaccine products in developing countries due to poor infrastructure. Plant-produced vaccines can potentially remove the need for cold-chain transportation and storage as vaccine antigens bioencapsulated in plant tissue could be used for oral administration or expressed in seeds that remain stable at ambient temperature, and be effectively delivered to the gut without degradation [193–195]. Although no plant-made therapeutic for HPV-related disease has reached clinical trial, there are several plant-based therapeutics that show

![Fig. 2. Ideal mechanism of a therapeutic vaccine against HPV-related malignancies.](image)

An ideal HPV therapeutic vaccine would elicit a strong cell-mediated immune response where CD4+ T-cells would provide support to CD8+ T-cells by secreting cytokines such as IFN-γ and IL2 labelling infected and malignant cells. Cytotoxic CD8+ T-cells would eliminate infected cells by secreting high amounts of granzyme B and perforin which lead to cell death. The response would be effective even in the presence of immunosuppressive cells [36].
## Table 1
Most recently completed and ongoing clinical trials.

| Vaccine type     | Vaccine name | Vaccine description                                                                 | HPV-related disease                                                              | Clinical phase | Status              | Expected completion | Clinical trial number |
|------------------|--------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------|---------------------|---------------------|-----------------------|
| Bacterial vector | ADXS11-001   | Attenuated live *Listeria* Encoding HPV 16 E7 vector                                  | Anal cancer                                                                      | I/II           | Active, not recruiting | February 2018   | NCT01671488           |
|                  |              |                                                                                      | Cervical carcinoma                                                              | I and II       | Active, not recruiting | December 2018  | NCT02164461           |
|                  |              |                                                                                      | Cervical cancer                                                                 | I and II       | Active, recruiting    | December 2019  | NCT02291055           |
|                  |              |                                                                                      | Head and neck cancer                                                            | II             | Active, not recruiting | October 2018   | NCT01266460           |
|                  |              |                                                                                      | Cervical cancer                                                                 | III            | Active, recruiting    | June 2021      | NCT02853604           |
|                  |              |                                                                                      | Anal and rectal cancer                                                           | II             | Active, not recruiting | March 2022     | NCT02399813           |
|                  |              |                                                                                      | Head and neck cancer, oropharyngean squamous cell carcinoma                     | II             | Active, not recruiting | August 2019    | NCT02020318           |
| Viral vector     | Vvax001      | Replication incompetent SFV HPV-16 E6/E7 vector                                       | Malignant cervical lesions                                                       | I              | Active, recruiting    | December 2017  | NCT03141463           |
|                  | TG4001       | MVA HPV-16 E6/E7/IL-2 vector                                                        | Oropharyngeal squamous cell carcinoma of the head and neck                       | Ib/II          | Active, recruiting    | May 2021       | NCT0260023            |
| Peptide-based    | DPX-E7       | Synthetic HPV16-E7 peptide 11-19 nanomer                                            | Head and neck cancer, cervical cancer, anal cancer                               | Ib/II          | Active, recruiting    | May 2023       | NCT02865135           |
|                  | ISA 101      | 9 HPV-16 E6 and 4 E7 SLPs                                                            | Solid tumours                                                                    | II             | Active, not recruiting | December 2018  | NCT02426892           |
|                  |              |                                                                                      | Cervical intraepithelial neoplasia                                               | II             | Active, recruiting    | August 2020    | NCT02401414           |
|                  |              |                                                                                      | HPV + tumours or malignant lesions                                               | I              | Active, recruiting    | December 2017  | NCT02621494           |
|                  |              |                                                                                      | Cervical cancer                                                                  | I              | Active, not recruiting | November 2022 | NCT02405221           |
|                  |              |                                                                                      | High-grade squamous intraepithelial lesions                                      | II             | Active, not recruiting | September 2018 | NCT02576561           |
|                  |              |                                                                                      | Cervical intraepithelial neoplasia                                               | II             | Completed             | March 2016     | NCT01392677           |
|                  |              |                                                                                      | Cervical intraepithelial neoplasia                                               | II             | Active, not recruiting | August 2018    | NCT02596243           |
|                  |              |                                                                                      | Cervical intraepithelial neoplasia 3                                             | Ib/II          | Active, recruiting    | October 2018   | NCT03206138           |
|                  |              |                                                                                      | Head and neck squamous cell cancer                                               | I/II           | Active, not recruiting | October 2017   | NCT02163057           |
|                  |              |                                                                                      | Cervical cancer                                                                  | I/II           | Active, not recruiting | March 2018     | NCT02172911           |
|                  |              |                                                                                      | High-grade squamous intraepithelial lesion of the cervix                        | III            | Active, not recruiting | August 2020    | NCT03185013           |
|                  |              |                                                                                      | High-grade cervical intraepithelial neoplasia                                   | I/II           | Active, recruiting    | December 2018  | NCT02529930           |
|                  |              |                                                                                      | HPV-16/18 E7 ZFNs                                                                | I              | Active, not recruiting | July 2017      | NCT02800369           |
|                  |              |                                                                                      | HPV malignant neoplasm                                                            | I              | Active, not recruiting | January 2019   | NCT03057912           |
|                  |              |                                                                                      | Uterine cervical neoplasms                                                       | I              | Active, recruiting    | August 2017    | NCT02866006           |
| Protein          | HP610.16     | DNA vaccine                                                                          | High-grade squamous intraepithelial lesion of the cervix                        | III            | Active, not recruiting | June 2016      | NCT02560811           |
|                  |              |                                                                                      | High-grade cervical intraepithelial neoplasia                                   | I/II           | Completed             | June 2016      | NCT02560811           |
| DNA              |                |                                                                                      | HPV-16/18 E6/7 TALEN or CRISPR/Cas9 plasmids                                    | I              | Not open               | January 2019   | NCT03057912           |
|                  | ZFN-603 and ZFN-758 | Plasmid encoding HPV-16 and – 18 E6 and E7 proteins fused to Fms-like tyrosine kinase-3 ligand | HPV-16/18 E6/7 Specific T Lymphocytes | I              | Active, recruiting    | August 2017    | NCT02866006           |
|                  | N/A           | Reombinant HPV16/18 E6/E7 expressing adeno-virus-infected B cells and monocytes     | Cervical, anal, vaginal and oropharyngeal cancer                                | I/II           | Completed             | June 2016      | NCT0280811            |
|                  |                |                                                                                      | Vulvar high-grade squamous intraepithelial lesions                              | I              | Active, recruiting    | February 2020  | NCT03197025           |
|                | N/A           | T cell receptor immunotherapy targeting HPV-16 E6                                  | Carcinoma (oropharyngeal, cervical, anal, vulval, penile)                       | I              | Active, recruiting    | October 2033   | NCT02379520           |
|                |                |                                                                                      | Cervical, vaginal, anal, penile and oropharyngeal cancer                        | I              | Active, recruiting    | January 2026   | NCT02858310           |
|                |                |                                                                                      | Cervical cancer-specific CAR-T cells                                           | I/II           | Active, recruiting    | December 2020  | NCT03567953           |

(continued on next page)
Table 1 (continued)

| Vaccine name | Vaccine description | HPV-related disease | Clinical phase | Status | Expected completion | Clinical trial number |
|--------------|---------------------|---------------------|----------------|--------|---------------------|-----------------------|
| pNGVL4a-sig/E7(detox)/HSP70 DNA prime, TA-HPV Combination therapy | High-grade cervical dysplasia | I | Active, recruiting | July 2017 | NCT00788164 |
| IRX-2 Regimen | Cervical or vulvar squamous intraepithelial neoplasia 3 | II | Active, recruiting | November 2022 | NCT03267680 |
| Ipilimumab anti-CTLA-4 monoclonal antibody + chemoradiotherapy | Advanced cervical cancer | I | Active, not recruiting | March 2017 | NCT01711515 |
| Ipilimumab anti-CTLA-4 monoclonal antibody | Metastatic or recurrent cervical cancer | II | Active, not recruiting | December 2017 | NCT01693783 |
| MEDI4736 + ISA101/ISA101b HPV-16 E6/E7 SLP vaccine + Carboplatin and Paclitaxel | Advanced or recurrent cervical cancer | I/II | Active, not recruiting | April 2021 | NCT02128126 |
| ISA101/ISA101b HPV-16 E6/E7 SLP vaccine | Head and neck cancer | Ia/IIb | Active, recruiting | July 2019 | NCT03162224 |
| VGX-3100 DNA vaccine + anti-PD-L1 monoclonal antibody | | | | | |
| MEDI0457 + Durvalumab | | | | | |

PVX nanofilaments carrying trastuzumab (a monoclonal antibody used as a targeted therapy in breast cancer patients) have been shown to induce apoptosis in breast cancer cell lines [199]. The use of tobacco mosaic virus (TMV)-derived particles for the delivery of drugs for chemotherapeutic treatments has been investigated, and the TMV-mediated in vivo delivery of phenanthroplatin has been confirmed in a triple negative breast cancer mouse model [200]. Cowpea mosaic virus (CPMV) nanoparticles have also been shown to stimulate the immune system to attack a number of cancers. Empty (eCPMV) particles have been produced in N. benthamiana [201] and have recently been used as targets for tumour immunotherapy via in situ vaccination to alter the tumour microenvironment. CPMV particles were shown to induce potent anti-tumour immune responses in melanoma, ovarian, colon and breast cancer models [202]. Additionally, the delivery of nucleic acid therapies using plant viruses has recently been reviewed by Lam and Steinmetz [203], and this system is said to have significant advantages over conventional mammalian viral vectors due to factors such as high production yields, increased safety due to no replication in mammalian cells, and no risk of insertional mutagenesis. This is a relatively new field which shows significant promise; however, more research is required [203].

4. Conclusions

There is an urgent need for therapeutic HPV vaccines to reduce the burden of cervical cancer, as current vaccines have no therapeutic effects. To date, no therapeutic vaccine has been approved for commercial use in the treatment of HPV infections and related malignancies. Nevertheless, numerous clinical trials show the progress that has been made using several vaccine strategies and two vaccine candidates, VGX-3100 DNA vaccine and ADXS11-001 bacterial vector vaccine, are both in phase III clinical trials, showing that there is promise of a vaccine in the near future. Plant expression systems have successfully been used to produce biologically relevant products and offer a platform to manufacture cheaper vaccines: these would be accessible to a greater population, specifically in low-middle income countries where the disease burden is greatest.

Funding

This work was supported by the Poliomyelitis Research Foundation (PRF) (15/12), the National Research Foundation of South Africa (NRF) and the Cancer Association of South Africa (Cansa) (2015). AC was supported by grants from the Carnegie Corporation of New York, the PRF and the University of Cape Town. RL and RJRY were supported by grants from the PRF and NRF.

References

[1] I. Abubakar, T. Tillmann, A. Banerjee, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013:
a systematic analysis for the general burden of disease study 2013, Lancet 385 (9963) (2015) 117–171.

[2] C. de Martel, et al., Global burden of cancers attributable to infections in 2008: a review and synthesis analysis, Lancet Oncol. 13 (6) (2012) 607–615.

[3] C. de Martel, et al., Worldwide burden of cancer attributable to HPV by site, country and HPV type, Int. J. Cancer (2017).

[4] M. Arbyn, et al., Human papillomavirus and related diseases: a global overview, Cancer Epidemiol. 36 (5) (2012) 569–586.

[5] B.H. Yang, et al., Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost, Int. J. Cancer 109 (3) (2004) 358–364.

[6] J. Ferlay, et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer 136 (5) (2015) E539–E836.

[7] J. Schiller, et al., Human papillomavirus: a review, Dermatol. Clin. 20 (2) (2002) 207–216.

[8] S.H. van der Burg, C.J. Melief, Therapeutic vaccination against human papillomavirus, Expert Opin. Biol. Ther. 8 (4) (2008) 421–431.

[9] J.M. Walboomers, et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J. Pathol. 189 (1) (1999) 15–43.

[10] A. Rowhani-Rahbar, et al., The impact of HIV status and type on the clearance of human papillomavirus infection, Expert Rev. Vaccin. 9 (8) (2010) 913–924.

[11] J.H. Kim, H.-J. Kim, Current status and future prospects for human papillomavirus vaccines, Arch. Pharm. Res. (2017) 1–14.

[12] C. Giorgi, R. Fransoni, Incidence and prevalence of human papillomavirus infections in plants, Expert Rev. Vaccin. 9 (8) (2010) 913–924.

[13] R. Fischer, et al., Plant-based production of biopharmaceuticals, Curr. Opin. Plant Biol. 46 (2) (2011) 152–158.

[14] M. Merlin, et al., Comparative evaluation of recombinant protein production in different biofactories: the green perspective, BioMed. Res. Int. 2014 (2014) 1–9.

[15] E.P. Ybicki, Plant-made vaccines for humans and animals, Plant Biotechnol. J. 8 (5) (2010) 620–637.

[16] S. Nandi, et al., Techno-economic analysis of a transient plant-based platform for monoclonal antibody production, MAbs (2016).

[17] G. Hansen, M.S. Wright, Recent advances in the transformation of plants, Trends Plant Sci. 6 (4) (1999) 226–231.

[18] P.A. Lessard, et al., Human papillomavirus vaccines, Arzneim. Forsch./Drug Res. 54 (12) (2004) 868–876.

[19] C. de Martel, et al., Worldwide burden of cancer attributable to HPV by site, country and HPV type, Int. J. Cancer (2017).

[20] J.M. Walboomers, et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J. Pathol. 189 (1) (1999) 15–43.

[21] A. Rowhani-Rahbar, et al., The impact of HIV status and type on the clearance of human papillomavirus infection, Expert Rev. Vaccin. 9 (8) (2010) 913–924.

[22] J.H. Kim, H.-J. Kim, Current status and future prospects for human papillomavirus vaccines, Arch. Pharm. Res. (2017) 1–14.

[23] C. Giorgi, R. Fransoni, Incidence and prevalence of human papillomavirus infections in plants, Expert Rev. Vaccin. 9 (8) (2010) 913–924.

[24] R. Fischer, et al., Plant-based production of biopharmaceuticals, Curr. Opin. Plant Biol. 46 (2) (2011) 152–158.

[25] M. Merlin, et al., Comparative evaluation of recombinant protein production in different biofactories: the green perspective, BioMed. Res. Int. 2014 (2014) 1–9.

[26] E.P. Ybicki, Plant-made vaccines for humans and animals, Plant Biotechnol. J. 8 (5) (2010) 620–637.

[27] S. Nandi, et al., Techno-economic analysis of a transient plant-based platform for monoclonal antibody production, MAbs (2016).

[28] G. Hansen, M.S. Wright, Recent advances in the transformation of plants, Trends Plant Sci. 6 (4) (1999) 226–231.

[29] P.A. Lessard, et al., Human papillomavirus vaccines, Arzneim. Forsch./Drug Res. 54 (12) (2004) 868–876.

[30] C. de Martel, et al., Worldwide burden of cancer attributable to HPV by site, country and HPV type, Int. J. Cancer (2017).

[31] J.M. Walboomers, et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J. Pathol. 189 (1) (1999) 15–43.

[32] A. Rowhani-Rahbar, et al., The impact of HIV status and type on the clearance of human papillomavirus infection, Expert Rev. Vaccin. 9 (8) (2010) 913–924.

[33] J.H. Kim, H.-J. Kim, Current status and future prospects for human papillomavirus vaccines, Arch. Pharm. Res. (2017) 1–14.

[34] C. Giorgi, R. Fransoni, Incidence and prevalence of human papillomavirus infections in plants, Expert Rev. Vaccin. 9 (8) (2010) 913–924.

[35] R. Fischer, et al., Plant-based production of biopharmaceuticals, Curr. Opin. Plant Biol. 46 (2) (2011) 152–158.

[36] M. Merlin, et al., Comparative evaluation of recombinant protein production in different biofactories: the green perspective, BioMed. Res. Int. 2014 (2014) 1–9.

[37] E.P. Ybicki, Plant-made vaccines for humans and animals, Plant Biotechnol. J. 8 (5) (2010) 620–637.

[38] S. Nandi, et al., Techno-economic analysis of a transient plant-based platform for monoclonal antibody production, MAbs (2016).

[39] G. Hansen, M.S. Wright, Recent advances in the transformation of plants, Trends Plant Sci. 6 (4) (1999) 226–231.

[40] P.A. Lessard, et al., Human papillomavirus vaccines, Arzneim. Forsch./Drug Res. 54 (12) (2004) 868–876.
